BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kontoghiorghes GJ. How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation? Expert Rev Hematol 2020;13:299-302. [PMID: 32037922 DOI: 10.1080/17474086.2020.1719359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kontoghiorghes GJ. Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. Int J Mol Sci 2022;23:6735. [PMID: 35743183 DOI: 10.3390/ijms23126735] [Reference Citation Analysis]
2 You H, Wang D, Wei L, Chen J, Li H, Liu Y, Hou Y. Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK Pathways. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/8281267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Timoshnikov VA, Selyutina OY, Polyakov NE, Didichenko V, Kontoghiorghes GJ. Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine. Int J Mol Sci 2022;23:1247. [PMID: 35163169 DOI: 10.3390/ijms23031247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Timoshnikov VA, Kichigina LA, Selyutina OY, Polyakov NE, Kontoghiorghes GJ. Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. Molecules 2021;26:5064. [PMID: 34443652 DOI: 10.3390/molecules26165064] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Kontoghiorghes GJ. Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines (Basel) 2021;8:36. [PMID: 34357152 DOI: 10.3390/medicines8070036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Puerta-Alcalde P, Champlin RE, Kontoyiannis DP. How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood 2020;136:2741-53. [PMID: 33301030 DOI: 10.1182/blood.2020005884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fingrut W, Law A, Lam W, Michelis FV, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Kim DDH. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. Ann Hematol 2021;100:789-98. [PMID: 33415423 DOI: 10.1007/s00277-020-04363-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sinha S, Pereira-Reis J, Guerra A, Rivella S, Duarte D. The Role of Iron in Benign and Malignant Hematopoiesis. Antioxid Redox Signal 2021;35:415-32. [PMID: 33231101 DOI: 10.1089/ars.2020.8155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Kontoghiorghes GJ, Kolnagou A, Kontoghiorghe CN, Mourouzidis L, Timoshnikov VA, Polyakov NE. Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. Medicines (Basel) 2020;7:E45. [PMID: 32751493 DOI: 10.3390/medicines7080045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
10 Kontoghiorghes GJ, Kontoghiorghe CN. Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 2020;9:E1456. [PMID: 32545424 DOI: 10.3390/cells9061456] [Cited by in Crossref: 15] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]